The Treatment of Plasmodium knowlesi Malaria

Trends in Parasitology

Volumn 33, Issue 3, 2017, Pages 242-253

  Barber, Bridget E ^a   Grigg, Matthew J ^a   William, Timothy ^a,b,c   Yeo, Tsin W ^a,d,e   Anstey, Nicholas M ^a  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b Queen Elizabeth Hospital   (Malaysia)

^c Jesselton Medical Centre   (Malaysia)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^e TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

artemisinin combination therapy; malaria; Plasmodium knowlesi; treatment

Indexed keywords

ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CHLOROQUINE PLUS PRIMAQUINE; CLINDAMYCIN; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; MEFLOQUINE; MULTIDRUG RESISTANCE PROTEIN 1; PRIMAQUINE; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; SULFADOXINE;

ANEMIA; ANTIBIOTIC THERAPY; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; CHILD; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; GENE MUTATION; HUMAN; IC50; IN VITRO STUDY; MALARIA FALCIPARUM; MICROSCOPE; MULTIPLE ORGAN FAILURE; PARASITE CLEARANCE; PARASITEMIA; PLASMODIUM; PLASMODIUM KNOWLESI; PLASMODIUM KNOWLESI MALARIA; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; COINFECTION; MALARIA; MALARIA, FALCIPARUM; SOUTHEAST ASIA;

ANTIMALARIALS; ARTEMISININS; ASIA, SOUTHEASTERN; CHLOROQUINE; COINFECTION; HUMANS; MALARIA; MALARIA, FALCIPARUM; PLASMODIUM KNOWLESI;

EID: 84994409153     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2016.09.002     Document Type: Review

References (75)

1. 1 Knowles, R., Das Gupta, B.M., A study of monkey-malaria and its experimental transmission to man. Indian Med. Gaz. 67 (1932), 246–249.
2. 2 Singh, B., et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 363 (2004), 1017–1024.
3. 3 Rajahram, G., et al. Falling Plasmodium knowlesi malaria death rate among adults despite rising incidence, Sabah, Malaysia, 2010-2014. Emerg. Infect. Dis. 22 (2016), 41–48.
4. 4 Yusof, R., et al. High proportion of knowlesi malaria in recent malaria cases in Malaysia. Malaria J., 13, 2014, 168.
5. 5 William, T., et al. Increasing incidence of Plasmodium knowlesi malaria following control of P. falciparum and P. vivax malaria in Sabah, Malaysia. PLoS Negl. Trop. Dis., 7, 2013, e2026.
6. 6 Singh, B., Daneshvar, C., Human infections and detection of Plasmodium knowlesi. Clin. Microbiol. Rev. 26 (2013), 165–184.
7. 7 Barber, B.E., et al. A prospective comparative study of knowlesi, falciparum and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and P. vivax but no mortality with early referral and artesunate therapy. Clin. Infect. Dis. 56 (2013), 383–397.
8. 8 Lee, K-S., et al. Morphological features and differential counts of Plasmodium knowlesi parasites in naturally acquired human infections. Malaria J., 8, 2009, 73.
9. 9 Rajahram, G., et al. Deaths due to Plasmodium knowlesi malaria in Sabah, Malaysia: association with reporting as P. malariae and delayed parenteral artesunate. Malaria J., 11, 2012, 284.
10. 10 Barber, B.E., et al. Limitations of microscopy to differentiate Plasmodium species in a region co-endemic for Plasmodium falciparum, Plasmodium vivax and Plasmodium knowlesi. Malaria J., 12, 2013, 8.
11. 11 William, T., et al. Changing epidemiology of malaria in Sabah, Malaysia: increasing incidence of Plasmodium knowlesi. Malaria J., 13, 2014, 390.
12. 12 Barber, B.E., et al. Evaluation of the sensitivity of a pLDH-based and an aldolase-based rapid diagnostic test for diagnosis of uncomplicated and severe malaria caused by PCR-confirmed Plasmodium knowlesi, Plasmodium falciparum, and Plasmodium vivax. J. Clin. Microbiol. 51 (2013), 1118–1123.
13. 13 Grigg, M.J., et al. Combining parasite lactate dehydrogenase-based rapid tests to improve specificity for the diagnosis of malaria due to Plasmodium knowlesi and other Plasmodium species in Sabah. Malaysia. J. Clin. Microbiol. 52 (2014), 2053–2060.
14. 14 Fatih, F.A., et al. Susceptibility of human Plasmodium knowlesi infections to anti-malarials. Malaria J., 12, 2013, 1186.
15. 15 Russell, B., et al. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob. Agents Chemother. 52 (2008), 1040–1045.
16. 16 Kerlin, D.H., et al. An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing. PLoS Negl. Trop. Dis., 6, 2012, e1772.
17. 17 Ekland, E.H., Fidock, D.A., In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. Int. J. Parasitol. 38 (2008), 743–747.
18. 18 Chaorattanakawee, S., et al. Ex vivo drug susceptibility testing and molecular profiling of clinical Plasmodium falciparum isolates from Cambodia from 2008 to 2013 suggest emerging piperaquine resistance. Antimicrob. Agents Chemother. 59 (2015), 4631–4643.
19. 19 Dahlström, S., et al. Plasmodium falciparum polymorphisms associated with ex vivo drug susceptibility and clinical effectiveness of artemisinin-based combination therapies in Benin. Antimicrob. Agents Chemother. 58 (2014), 1–10.
20. 20 Phompradit, P., et al. Four years’ monitoring of in vitro sensitivity and candidate molecular markers of resistance of Plasmodium falciparum to artesunate-mefloquine combination in the Thai–Myanmar border. Malaria J. 13 (2014), 1–10.
21. 21 Lee, K-S., et al. Plasmodium knowlesi: reservoir hosts and tracking the emergence in humans and macaques. PLoS Pathog., 7, 2011, e1002105.
22. 22 Imai, N., et al. Transmission and control of Plasmodium knowlesi: a mathematical modelling study. PLoS Negl. Trop. Dis., 8, 2014, e2978.
23. 23 Tyagi, R.K., et al. Discordance in drug resistance-associated mutation patterns in marker genes of Plasmodium falciparum and Plasmodium knowlesi during coinfections. J. Antimicrob. Chemother. 68 (2013), 1081–1088.
24. 24 Grigg, M.J., et al. Dihydrofolate-reductase mutations in Plasmodium knowlesi appear unrelated to selective drug pressure from putative human-to-human transmission in Sabah, Malaysia. PLoS ONE, 11, 2016, e0149519.
25. 25 Assefa, S., et al. Population genomic structure and adaptation in the zoonotic malaria parasite Plasmodium knowlesi. Proc. Natl. Acad. Sci. U.S.A. 112 (2015), 13027–13032.
26. 26 Pinheiro, M.M., et al. Plasmodium knowlesi genome sequences from clinical isolates reveal extensive genomic dimorphism. PLoS ONE, 10, 2015, e0121303.
27. 27 Daneshvar, C., et al. Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections. Malaria J., 9, 2010, 238.
28. 28 Grigg, M.J., et al. Artesunate–mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial. Lancet Infect. Dis. 16 (2015), 180–188.
29. 29 William, T., et al. Severe Plasmodium knowlesi malaria in a tertiary hospital, Sabah. Malaysia. Emerg. Infect. Dis. 17 (2011), 1248–1255.
30. 30 Setiadi, W., et al. A zoonotic human infection with simian malaria, Plasmodium knowlesi, in Central Kalimantan, Indonesia. Malaria J., 15, 2016, 1.
31. 31 World Health Organization. Guidelines for the Treatment of Malaria. 3rd edn, 2015, World Health Organization.
32. 32 Bronner, U., et al. Swedish traveller with Plasmodium knowlesi malaria after visiting Malaysian Borneo. Malaria J., 8, 2009, 15.
33. 33 Tanizaki, R., et al. First case of Plasmodium knowlesi infection in a Japanese traveller returning from Malaysia. Malaria J. 12 (2013), 1–4.
34. 34 Tripathi, R., et al. Mefloquine resistance reversal action of ketoconazole–a cytochrome P 450 inhibitor, against mefloquine-resistant malaria. Parasitology 130 (2005), 475–479.
35. 35 Singh, P., Dutta, G., Antimalarial activity of mefloquine and chloroquine against blood induced Plasmodium knowlesi infection in rhesus monkeys. Indian J. Med. Res. 73 (1981), 23–28.
36. 36 Lau, Y.L., et al. Plasmodium knowlesi reinfection in human. Emerg. Infect. Dis. 17 (2011), 1314–1316.
37. 37 Cox-Singh, J., et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin. Infect. Dis. 46 (2008), 165–171.
38. 38 Phillips-Howard, P.A., ter Kuile, F.O., CNS adverse events associated with antimalarial agents. Drug Saf. 12 (1995), 370–383.
39. 39 Ehrhardt, J., et al. Plasmodium knowlesi and HIV co-infection in a German traveller to Thailand. Malaria J., 12, 2013, 283.
40. 40 Figtree, M., et al. Plasmodium knowlesi in human, Indonesian Borneo. Emerg. Infect. Dis., 16, 2010, 672.
41. 41 Hoosen, A., Shaw, M., Plasmodium knowlesi in a traveller returning to New Zealand. Travel. Med. Infect. Dis. 9 (2011), 144–148.
42. 42 Mackroth, M.S., et al. Rapid-antigen test negative malaria in a traveler returning from Thailand, molecularly diagnosed as Plasmodium knowlesi. Open Forum Infect. Dis., 3, 2016, ofw039.
43. 43 Douglas, N.M., et al. Artemisinin combination therapy for vivax malaria. Lancet Infect. Dis. 10 (2010), 405–416.
44. 44 Grigg, M.J., et al. Efficacy of artesunate-mefloquine against high-grade chloroquine-resistant Plasmodium vivax malaria in Malaysia: an open-label randomised controlled trial. Clin. Infect. Dis. 62 (2016), 1403–1411.
45. 45 Price, R.N., et al. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect. Dis. 14 (2014), 982–991.
46. 46 van Hellemond, J., et al. Human Plasmodium knowlesi infection detected by rapid diagnostic tests for malaria. Emerg. Infect. Dis, 15, 2009, 1478.
47. 47 Nakaviroj, S., et al. An autochthonous case of severe Plasmodium knowlesi malaria in Thailand. Am. J. Trop. Med. Hyg. 92 (2015), 569–572.
48. 48 Ninan, T., et al. Plasmodium knowlesi malaria infection in human. Brunei Int. Med. J. 8 (2012), 358–361.
49. 49 Seilmaier, M., et al. Severe Plasmodium knowlesi infection with multi-organ failure imported to Germany from Thailand/Myanmar. Malaria J, 13, 2014, 422.
50. 50 Orth, H., et al. Plasmodium knowlesi infection imported to Germany, January 2013. Euro. Surveill. 18 (2013), 1–3.
51. 51 Dondorp, A., et al. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366 (2005), 717–725.
52. 52 Dondorp, A.M., et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376 (2010), 1647–1657.
53. 53 Willmann, M., et al. Laboratory markers of disease severity in Plasmodium knowlesi infection: a case control study. Malaria J., 11, 2012, 363.
54. 54 World Health Organization. Severe malaria. Trop. Med. Int. Health 19 (2014), 7–131.
55. 55 Jauréguiberry, S., et al. Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood 124 (2014), 167–175.
56. 56 Gómez-Junyent, J., et al. Delayed haemolysis after artesunate therapy in a cohort of patients with severe imported malaria due to Plasmodium falciparum. Enferm. Infecc. Microbiol. Clin., 2015, 10.1016/j.eimc.2015.11.003 Published online December 17, 2015.
57. 57 Barber, B.E., et al. Intravascular haemolysis with haemoglobinuria in a splenectomized patient with severe Plasmodium knowlesi malaria. Malaria J., 15, 2016, 462.
58. 58 Daneshvar, C., et al. Clinical and laboratory features of human Plasmodium knowlesi infection. Clin. Infect. Dis. 49 (2009), 852–860.
59. 59 Lee, C.E., et al. Human Plasmodium knowlesi infections in Klang Valley, Peninsular Malaysia: a case series. Med. J. Malaysia 65 (2010), 63–65.
60. 60 Hanson, J., et al. The fluid management of adults with severe malaria. Crit. Care 18 (2014), 1–9.
61. 61 Hanson, J.P., et al. Fluid resuscitation of adults with severe falciparum malaria: effects on acid-base status, renal function, and extravascular lung water. Crit. Care Med. 41 (2013), 972–981.
62. 62 Aung, N.M., et al. The safety of a conservative fluid replacement strategy in adults hospitalised with malaria. PLoS ONE, 10, 2015, e0143062.
63. 63 Douglas, N.M., et al. Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study. PLoS Med., 10, 2013, e1001575.
64. 64 Barber, B.E., et al. Plasmodium knowlesi malaria in children. Emerg. Infect. Dis. 17 (2011), 814–820.
65. 65 Barber, B.E., et al. Plasmodium knowlesi malaria in pregnancy. J. Infect. Dis. 211 (2014), 1104–1110.
66. 66 Dellicour, S., et al. Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: a prospective cohort study in western Kenya. Malaria J. 14 (2015), 1–9.
67. 67 Moore, K.A., et al. Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. Lancet Infect. Dis. 16 (2016), 576–583.
68. 68 Berry, A., et al. Case report: imported Plasmodium knowlesi malaria in a French tourist returning from Thailand. Am. J. Trop. Med. Hyg. 84 (2011), 535–538.
69. 69 Ennis, J., et al. Simian malaria in a US traveler–New York, 2008. Morbid. Mortal. Weekly Rep. 58 (2009), 229–232.
70. 70 Fan, L., et al. Plasmodium knowlesi infection: a diagnostic challenge. BMJ Case Rep., 2013, 10.1136/bcr-2013-009558 Published online April 22, 2013.
71. 71 Kantele, A., et al. Monkey malaria in a European traveler returning from Malaysia. Emerg. Infect. Dis. 14 (2008), 1434–1436.
72. 72 Kuo, M-C., et al. A case report of simian malaria, Plasmodium knowlesi, in a Taiwanese traveler from Palawan Island, the Philippines. Taiwan Epidemiol. Bull. 25 (2009), 178–191.
73. 73 Tang, T., et al. First case of detection of Plasmodium knowlesi in Spain by Real Time PCR in a traveller from Southeast Asia. Malaria J., 9, 2010, 219.
74. 74 Link, L. et al. (2010) Molecular detection of Plasmodium knowlesi in a Dutch traveler by real-time PCR. J. Clin. Microbiol. 50, 2523–2524.
75. 75 Kroidl, I., et al. [Monkey malaria (Plasmodium knowlesi infection) after travelling to Thailand]. Dt. med. Wschr. 140 (2015), 815–817.